Conference Paper

After diagnosis, patients with low-grade gliomas (WHO grade II) can experience challenges that impact their health-related quality of life (HRQoL). One such impairment in HRQoL is neurocognitive dysfunction whether it is due to the underlying tumor or due to treatment including surgery, radiation, and chemotherapy. We sought to understand neurocognition in low-grade glioma patients and the associations with HRQoL including perceptions of their own neurocognition. In this study, 31 subjects with low-grade glioma underwent neurocognitive testing using a computerized program that assessed neurocognitive domains of cognitive flexibility, complex attention, executive functioning, psychomotor speed, processing speed, reaction time, verbal and visual memory. These measures and two HRQoL measures, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and Functional Assessment of Cancer Therapy-Cognition Function (FACT-Cog), were completed at baseline and 6 months later. Of the 31 subjects enrolled, majority were male (N=18, 58.1%), had ≥ 16 years of education (N=18, 58.1%), had KPS ≥90 (N=21, 67.7%), and had gross total resection (N=21, 67.7%). Only 4 subjects had prior radiation therapy, and 35.5% had prior chemotherapy. For all neurocognitive domains, there was no significant change in test scores over the 6 month period and a majority performed well with only 16.1-45.2% having standardized neurocognitive scores more than one standard deviation below the mean. Spearman’s rank correlation coefficients indicated perceived cognitive impairment, as measured by FACT-Cog, was significantly correlated with performance on domains of psychomotor speed (p=0.0049), complex attention (p=0.0059), cognitive flexibility (p=0.0133), and executive functioning (p=0.0279). Memory domains and reaction time did not correlate with perceived cognition on FACT-Cog. Less perceived cognitive impairment in low-grade glioma patients is associated with better performance on neurocognitive tests involving complex tasks such as complex attention and executive function. Identification of these particular impairments in low-grade glioma patients has the potential to improve HRQoL outcomes.

Full Text

Cited Authors

  • Peters, K; Affronti, ML; Woodring, S; Minchew, J; Lipp, E; McSherry, F; Herndon, J; Randazzo, D; Desjardins, A; Vlahovic, G; Friedman, H; Barboriak, D

Duke Contributors

Published Date

  • November 1, 2016

Published In

Volume / Issue

  • 18 / suppl_6

Start / End Page

  • vi122 - vi122

Published By

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

International Standard Serial Number (ISSN)

  • 1522-8517

Digital Object Identifier (DOI)

  • 10.1093/neuonc/now212.507

Conference Name

  • 21st Annual Scientific Meeting and Educations Day of the Society for Neuro-Oncology

Conference Location

  • Scottsdale, AZ

Conference Start Date

  • November 17, 2016

Conference End Date

  • November 20, 2016